Andere Sprachen Sino Biopharmaceutical Limited

Aktien

A0CBDJ

KYG8167W1380

1177

Markt geschlossen - Hong Kong S.E. Andere Börsenplätze 10:08:20 26.04.2024			% 5 Tage	% 1. Jan.
2.77 ^HKD	+1.09%		+13.99%	-20.17%

25.04.	Sino Biopharm schließt Phase-I-Studie für Hepatitis-B-Medikament ab	MT
22.04.	Beruhigung der geopolitischen Spannungen beflügelt asiatische Aktienmärkte	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Sino Biopharm Completes Phase I Study of Hepatitis B Drug	25.04.
Lull in Geopolitical Tensions Lifts Asian Stock Markets	22.04.
Hong Kong shares jump on policy support; China slips	22.04.
Borse Cina : chiudono miste, in rialzo Hong Kong con decisione su tassi	22.04.
Hong Kong shares jump 1.5% on policy support; China slips	22.04.
Sino Biopharmaceutical Reaches Primary Endpoint for Clinical Research of Myelofibrosis Drug	19.04.
Sino Biopharmaceutical Limited Announces Category 1 Innovative Drug Rovadicitinib Obtained Positive Results in Key Clinical Research for Registration	18.04.
Sino Biopharm EBT Buys Back HK$12 Million Worth of Shares	17.04.
Sino Biopharmaceutical Presents Cancer Drug's Phase-II Clinical Trial Results at AACR 2024	11.04.
Sino Biopharmaceutical Trustee Repurchases Shares	08.04.
Sino Biopharmaceutical to Develop Boehringer Ingelheim's Cancer Treatments in China	08.04.
Sino Biopharmaceutical Limited Enters into Strategic Partnership with Boehringer Ingelheim on Innovative Oncology Portfolio in China	08.04.
Sino Biopharmaceutical's Attributable Profit Drops 8.3% in 2023	29.03.
Sino Biopharm (1177.HK) Announces 2023 Annual Results	29.03.
Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 5 July 2024	28.03.
Sino Biopharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
Sino Biopharmaceutical's Diagnostic Agent Injection Gets Marketing Nod in China	25.03.
Sino Biopharmaceutical Limited Announces Approval for Marketing of Iopromide Injection	24.03.
Sino Biopharmaceutical's Developing Two Drugs for MASH	15.03.
Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225"	15.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Sino Biopharmaceutical Limited

Aktien

A0CBDJ

KYG8167W1380

1177

Andere Sprachen

Filter